

27th July, 2021

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
Ist Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/I, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter ended 30th June, 2021

The presentation on unaudited Consolidated Financial Results for the quarter ended 30th June, 2021 to be made to analysts is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

MAHESH AGRAWAL

VP (LEGAL) & COMPANY SECRETARY

Encl: A/a



Q1 FY 2021-22

Revenues: Summary



Revenue: Summary

Revenues (Rs cr)	Q1 FY22	Q1 FY21	Gr%
India	1,093	925	18%
United States	266	373	-29%
Germany	260	246	5%
Brazil	153	140	9%
Other countries	217	234	-7%
Others (Inc. CRAMS)	146	138	6%
Total	2,134	2,056	4%

